(-0.72%) 5 079.37 points
(-0.85%) 38 060 points
(-0.84%) 15 848 points
(-1.04%) $81.77
(-0.64%) $2.02
(-2.18%) $2 306.30
(-3.63%) $26.66
(-1.80%) $944.20
(0.39%) $0.936
(0.95%) $11.09
(0.41%) $0.799
(0.26%) $93.54
Live Chart Being Loaded With Signals
Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant...
Stats | |
---|---|
Šios dienos apimtis | 10.25M |
Vidutinė apimtis | 9.29M |
Rinkos kapitalizacija | 2 714.75B |
EPS | ¥0 ( 2024-04-25 ) |
Last Dividend | ¥30.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 558.67 |
ATR14 | ¥0.662 (0.04%) |
Tūris Koreliacija
Astellas Pharma Inc. Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Astellas Pharma Inc. Koreliacija - Valiuta/Žaliavos
Astellas Pharma Inc. Finansinės ataskaitos
Annual | 2023 |
Pajamos: | ¥1 603.67B |
Bruto pelnas: | ¥1 212.37B (75.60 %) |
EPS: | ¥9.50 |
FY | 2023 |
Pajamos: | ¥1 603.67B |
Bruto pelnas: | ¥1 212.37B (75.60 %) |
EPS: | ¥9.50 |
FY | 2022 |
Pajamos: | ¥1 518.62B |
Bruto pelnas: | ¥1 230.27B (81.01 %) |
EPS: | ¥54.24 |
FY | 2022 |
Pajamos: | ¥1 296.16B |
Bruto pelnas: | ¥1 043.15B (80.48 %) |
EPS: | ¥67.08 |
Financial Reports:
No articles found.
Astellas Pharma Inc. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥30.00 (N/A) |
¥0 (N/A) |
¥30.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥3.00 | 2000-03-28 |
Last Dividend | ¥30.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 48 | -- |
Total Paid Out | ¥591.00 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.71 | -- |
Div. Sustainability Score | 8.06 | |
Div.Growth Potential Score | 6.81 | |
Div. Directional Score | 7.43 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
8011.T | Ex Dividend Junior | 2024-02-28 | Sporadic | 0 | 0.00% | |
7250.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
6486.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
5703.T | Ex Dividend Junior | 2023-09-28 | Annually | 0 | 0.00% | |
4523.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
3681.T | Ex Dividend Junior | 2023-12-28 | Annually | 0 | 0.00% | |
2975.T | Ex Dividend Knight | 2023-11-29 | Semi-Annually | 0 | 0.00% | |
1827.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
9832.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
8897.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.00805 | 1.500 | 9.84 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.00362 | 1.200 | 9.88 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.00817 | 1.500 | -1.020 | -1.530 | [0.1 - 1] |
payoutRatioTTM | 9.04 | -1.000 | 10.00 | -10.00 | [0 - 1] |
currentRatioTTM | 0.929 | 0.800 | -0.354 | -0.283 | [1 - 3] |
quickRatioTTM | 0.687 | 0.800 | -0.663 | -0.530 | [0.8 - 2.5] |
cashRatioTTM | 0.261 | 1.500 | 9.66 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.258 | -1.500 | 5.70 | -8.56 | [0 - 0.6] |
interestCoverageTTM | 8.97 | 1.000 | 7.79 | 7.79 | [3 - 30] |
operatingCashFlowPerShareTTM | 97.61 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 51.61 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.576 | -1.500 | 7.69 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.797 | 1.000 | 0.0457 | 0.0457 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0672 | 1.000 | -0.657 | -0.657 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.190 | 1.000 | -0.0541 | -0.0541 | [0.2 - 2] |
assetTurnoverTTM | 0.449 | 0.800 | -0.338 | -0.271 | [0.5 - 2] |
Total Score | 8.06 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 210.39 | 1.000 | 10.00 | 0 | [1 - 100] |
returnOnEquityTTM | 0.00817 | 2.50 | -0.656 | -1.530 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 51.61 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 4.62 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 97.61 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 9.04 | 1.500 | 10.00 | -10.00 | [0 - 1] |
pegRatioTTM | 63.54 | 1.500 | 10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.109 | 1.000 | 9.77 | 0 | [0.1 - 0.5] |
Total Score | 6.81 |
Astellas Pharma Inc.
Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mirabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical trial collaboration with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and an agreement with BANDAI NAMCO Entertainment Inc. for the development of smartphone exercise support application. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest; research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platform, as well as agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694; and collaboration agreement with Cytokinetics, Incorporated. The company has a strategic collaboration and license agreement with Minovia Therapeutics Ltd. for the research, development, and commercialization of cell therapy programs for diseases caused by mitochondrial dysfunction. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.